Effects of statins on lipoprotein fractions

International Congress Series

Volumn 1253, Issue C, 2003, Pages 247-252

  Cortese, Claudio ^a   Liberatoscioli, Laura ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Coronary artery disease; Hyperlipidemias; Hypolipidemic agents; Lipoproteins; Statins

Indexed keywords

EID: 62549108068     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(03)00787-8     Document Type: Article

References (21)

1. The Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
2. Shepherd, J., Cobbe, S.M., Fordl, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333 (1995), 1301–1307.
3. Sacks, F.M., Pfeffer, M.A., Moye, L.A., et al., for the Cholesterol and Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335 (1996), 1001–1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339 (1998), 1349–1357.
5. Downs, J.R., Clearfield, M., Weis, S., et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279 (1998), 1615–1622.
6. The Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo controlled trial. Lancet 360 (2002), 7–22.
7. Endo, A., The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33 (1992), 1569–1582.
8. Goldstein, J.L., Brown, MS., Regulation of the mevalonate pathway. Nature 343 (1990), 425–430.
9. Huff, M.W., Burnett, J.R., 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr. Opin. Lipidol. 8 (1997), 138–145.
10. Appel, S., Dingemanse, L., Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 32 (1996), 39–55.
11. Christians, U., Jacobsen, W., Floren, L.C., Metabolism and drug interactions of £-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol. Ther. 80 (1998), 1–34.
12. Cilla, D.D. Jr., Whitfield, L.R., Gibson, D.M., Sedman, A.J., Posvar, E.L., Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60 (1996), 687–695.
13. Lennernas, H., Fager, G., Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32 (1997), 403–425.
14. Fischer, W., Johanson, L., Heitz, F., et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27 (1999), 410–416.
15. McClellan, K.J., Wiseman, L.R., McTavish, D., Cerivastatin. Drugs 55 (1998), 415–420.
16. Fujino, H., Yamada, I., Shimada, S., Yoneda, M., Kojima, J., Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33:1 (2003 (Jan.)), 27–41.
17. Jones, P., Kafonek, S., Laurora, I., Hunninghake, D., for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 81 (1998), 582–587.
18. Bakker-Arkema, R.G., Davidsohn, M.H., Goldstein, R.J., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275 (1996), 128–133.
19. Stein, E.A., Lane, M., Laskarzewski, P., Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81 (1998), 66B–69B.
20. Illingworth, D.R., Crouse, J.R. III, Hunninghake, D.B., Davidson, M.H., Escobar, I.D., Stalenhoef, A.F.H., Paragh, G., Ma, P.T.S., Liu, M., Melini, M.R., O'Grady, L., Mercuri, M., Mitchel for the Simvastatin Atorvasatatin HDL Study Group. A comparison of Simvastatin and Atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr. Med. Res. Opin. 117:1 (2001), 43–50.
21. Wierzbicki, A.S., Mikhailidis, D.P., Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int. J. Cardiol. 84 (2002), 53–57.